Byungdoo A Yi

US Patent:

20120009158, Jan 12, 2012

Filed:

Jun 17, 2011

Appl. No.:

13/163339

Inventors:

Kenneth R. Chien - Cambridge MA, US
Huansheng Xu - Malden MA, US
Byungdoo Alexander Yi - Boston MA, US

Assignee:

THE GENERAL HOSPITAL CORPORATION - Boston MA

International Classification:

A61K 35/12
C12Q 1/02
A61P 9/00
C12N 5/071
C12N 15/85

US Classification:

424 937, 435377, 435455, 435325, 435366, 435 29

Abstract:

The present invention generally relates to methods and compositions to generate a secondary iPS (2iPS) cell to produce somatic cells of a rare differentiation cell type fate. In some embodiments, the method relates to an increase in efficiency of differentiation and production of high yields of somatic cells of a rare differentiation cell type fate produced from secondary iPS (2iPS) cells as compared to their differentiation from other pluripotent stem cell sources such as ES cells or primary iPS cells. In some embodiments, the present invention relates to compositions, methods and systems for reprogramming a first somatic cell into a primary iPS cell, where the primary iPS cell is then differentiated along a selected linage to produce a second somatic cell, which is then reprogrammed to a secondary iPS cell (2iPS) cell. The 2iPS cell has a high efficiency of differentiating into a cell of the same cell type as the second somatic cell, e.g., a somatic cells of a rare differentiation cell type fate such as but not limited to a ventricular cardiomyocyte, a pancreatic β-cell or a hepatic cell. In some embodiments, the first somatic cell is a fibroblast, or a cardiac cell, but is not limited to cardiac fibroblast cells. In some embodiments, the present invention relates to compositions, methods and systems to produce ventricular cardiomyocytes from secondary induced pluripotent stem cells (iPSC), where the iPSC are themselves generated from ventricular cardiomyocytes. The secondary iPS (2iPS) cell generated from ventricular cardiomyocytes have a higher cardiomyogenic potential and high cardiomyogenic yield as compared to primary iPSC, and are useful in drug discovery, disease modeling and cell-based therapy.

US Patent:

20200376080, Dec 3, 2020

Filed:

Dec 21, 2018

Appl. No.:

16/955023

Inventors:

- Basel, CH
Byungdoo Alexander YI - Cambridge MA, US

International Classification:

A61K 38/18
A61K 45/06
A61P 3/00
A61P 3/06

Abstract:

Provided herein are methods of treating, preventing, and managing metabolic or cardiovascular disorders and methods of reducing cardiovascular risk with FGF21 protein variants, including Fc-FGF21 variant fusion proteins.